1. Home
  2. UYSC vs NVNO Comparison

UYSC vs NVNO Comparison

Compare UYSC & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UYSC
  • NVNO
  • Stock Information
  • Founded
  • UYSC 2024
  • NVNO 1987
  • Country
  • UYSC United States
  • NVNO United States
  • Employees
  • UYSC N/A
  • NVNO N/A
  • Industry
  • UYSC Blank Checks
  • NVNO Medical/Dental Instruments
  • Sector
  • UYSC Finance
  • NVNO Health Care
  • Exchange
  • UYSC Nasdaq
  • NVNO Nasdaq
  • Market Cap
  • UYSC 76.5M
  • NVNO 71.0M
  • IPO Year
  • UYSC 2025
  • NVNO N/A
  • Fundamental
  • Price
  • UYSC $10.04
  • NVNO $4.01
  • Analyst Decision
  • UYSC
  • NVNO
  • Analyst Count
  • UYSC 0
  • NVNO 0
  • Target Price
  • UYSC N/A
  • NVNO N/A
  • AVG Volume (30 Days)
  • UYSC 8.0K
  • NVNO 141.7K
  • Earning Date
  • UYSC 01-01-0001
  • NVNO 07-30-2025
  • Dividend Yield
  • UYSC N/A
  • NVNO N/A
  • EPS Growth
  • UYSC N/A
  • NVNO N/A
  • EPS
  • UYSC N/A
  • NVNO N/A
  • Revenue
  • UYSC N/A
  • NVNO N/A
  • Revenue This Year
  • UYSC N/A
  • NVNO N/A
  • Revenue Next Year
  • UYSC N/A
  • NVNO N/A
  • P/E Ratio
  • UYSC N/A
  • NVNO N/A
  • Revenue Growth
  • UYSC N/A
  • NVNO N/A
  • 52 Week Low
  • UYSC $10.05
  • NVNO $2.03
  • 52 Week High
  • UYSC $11.00
  • NVNO $6.48
  • Technical
  • Relative Strength Index (RSI)
  • UYSC N/A
  • NVNO 49.82
  • Support Level
  • UYSC N/A
  • NVNO $3.86
  • Resistance Level
  • UYSC N/A
  • NVNO $4.36
  • Average True Range (ATR)
  • UYSC 0.00
  • NVNO 0.29
  • MACD
  • UYSC 0.00
  • NVNO -0.06
  • Stochastic Oscillator
  • UYSC 0.00
  • NVNO 10.34

About UYSC UY Scuti Acquisition Corp. Ordinary Shares

UY Scuti Acquisition Corp is a newly organized blank check company.

About NVNO enVVeno Medical Corporation

enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.

Share on Social Networks: